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Letter to the Editor: A Randomized, Double-Blinded, Placebo-Controlled, Cross Over Study 
Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of 
Migraine 
John C. Hagan III, M.D., FACS, FAAO 
Discover Vision Centers. Kansas City, MO 
 I am an experienced and published researcher using timolol beta-blocker ophthalmic 
eyedrops for the successful treatment of acute migraines.1-5 The above referenced paper contains 
many errors in study design and conduct.6 The statistics, discussion, and conclusion are 
misleading. 
 Beta blockers are FDA approved and often effective for chronic migraine prevention by 
taking daily oral doses that maintain therapeutic blood levels. For acute migraine, oral beta 
blockers have not worked well because they take too long to achieve therapeutic blood levels.1,2 
There are three other ways beta blocker solutions can be used to quickly achieve therapeutic 
blood levels. The first is promptly and properly applied topical beta blocker eyedrops to normal 
eyes/eyelids/nasolacrimal ducts/nasal mucosa. Faster is sublingual beta blocker drops and the 
fastest is beta blocker nasal spray.1,2 These last two preferred methods were not discussed in 
Aggarwal’s paper.6  
Ophthalmologists spend their careers listening to patients complain about the difficulties 
of using eye drops. Sublingual application has been studied and found effective for glaucoma 
control in a subgroup of drop-challenged patients.7 Most acute migraine patients I have treated 
with timolol 0.5% eye drops prefer to take them sublingual for ease of application and efficacy 
rather than topical to the eyes.   
 Absorption of beta blockers and subsequent beta receptor blockade has been studied.1,8 
Of these three methods, nasal application has been shown to the be fastest and equivalent to 
intravenous beta blocker administration in a study of 80 human volunteers.8 Until recently, no 
beta blocker nasal spray was commercially available. O’Brien Pharmacy (https://obrienrx.com/) 
now prepares a compounded nasal spray of timolol with MucoluxTM delivering 0.125 mg/0.1 ml 
spray. The nasal spray is shaken and one spray delivered into each nostril at first onset of 
migraine symptoms. Patients may also take their other acute migraine medications with the beta 
blocker nasal spray. If migraine headache persists a second set of one spray per nostril is 
repeated in 10-15 minutes. A maximum of 4 sprays per 24 hours is specified. An O’Brien 
pharmacist contacts the patient on receiving a prescription from a licensed physician and inquires 
about beta blocker contra-indication and instructs on use. The cost of the medication at this 
writing is $30 for a 10 ml bottle plus postage. All future research on using beta blockers for acute 
migraine should be done using nasal delivery. I have no financial interest in this product. 
 The Aggarwal study6 has so many other deficiencies that for reasons of space I can only 
list them without much discussion: patients not beta blocker naïve were included; retrospective 
exclusion of them taints the already scant data; the patients were not instructed to take the eye 
drops as quickly as possible with migraine onset; instead they had to fill out a questionnaire 
about the migraine; the study does not state if or when a second set of eye drops were to be 
instilled (ideally 10 minutes after the first if migraine persists); it is not stated whether patients 
were allowed to take their usual acute migraine medications which they should have been; the 
migraine patients were recruited from a tertiary neurological referral center with a high number 
of refractory migraineurs. Most important, per their own analysis, the number of patients studied 
does not allow any reliable statistical validity which Aggarwal nevertheless erroneously claimed.  
Their discussion does not include consideration of the more effective and easier to use sublingual 
or nasal beta blocker administration; the discussion attributes findings and conclusions to another 
study9 that are inaccurate and ignores optimistic statements of those authors about further study 
of beta blockers for acute migraine.10 
 Cossack et al.9 reported that 4 of their 10 studied patients found the masked beta blocker 
eye drop a useful addition to their acute migraine therapy versus only 1 in favor of masked 
placebo. They did allow a second set of eye drops but no sooner than 30 minutes because of 
Institutional Review Board concerns. They did discuss that if used 10-15 minutes post first 
insertion it might have improved their results. They did not claim statistical significance of their 
study but determined that “A future crossover study will require 86 patients to power a study 
with α≤0.05 and β≤0.2.” 9,10 Cossack and Gratton conclude their discussion, “We believe that, 
together, our work advances the notion that timolol drops are a safe effective, and already 
widely available abortive treatment in select migraineurs.”10  Neither the Cossack et al.9 or the 
Aggarwal studies were large enough for statistical significance so it is a misrepresentation for 
Aggarwal et al.6 to state "we now have two randomized-controlled trials that would not 
demonstrate a marked effect of the drug compared to placebo."  
 I hope that either the pharmaceutical industry or grant funding will soon conduct a large, 
adequately-powered (N ≥ 86), placebo-controlled, cross-over study using the newly available 
nasal spray delivery as a novel, safe, relatively inexpensive treatment for acute migraines.  
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